Ferrer I, Blanco-Aparicio C, Peregrina S, Cañamero M, Fominaya J, Cecilia Y, Lleonart M, Hernandez-Losa J, Ramon Y Cajal S, Carnero A.
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.
Cell Cycle. 2011 Aug 15;10(16).
Ferrer I, Peregrino S, Cañamero M, Cecilia Y, Blanco-Aparicio C, Carnero A.
Spinophilin loss contributes to tumorigenesis in vivo.
Cell Cycle. 2011 Jun 15;10(12):1948-55.
Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, Suarez R, Verge M, Marin JJ, Hernandez-Losa J, Cajal SR, Paz-Ares L, Carnero A.
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.
J Pathol. 2011 Sep;225(1):73-82.
Blanco-Aparicio C, Collazo AM, Oyarzabal J, Leal JF, Albarán MI, Lima FR, Pequeño B, Ajenjo N, Becerra M, Alfonso P, Reymundo MI, Palacios I, Mateos G, Quiñones H, Corrionero A, Carnero A, Pevarello P, Lopez AR, Fominaya J, Pastor J, Bischoff JR.
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Cancer Lett. 2011 Jan 28;300(2):145-53.
Cubo L, Hambley TW, Sanz Miguel PJ, Carnero A, Navarro-Ranninger C, Quiroga AG.
The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Dalton Trans. 2011 Jan 14;40(2):344-7.
Carnero A, Lleonart ME.
Epigenetic mechanisms in senescence, immortalisation and cancer.
Biol Rev Camb Philos Soc. 2011 May;86(2):443-55.
Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.
PloS One. 2010 19;5(2):e9305.
Zanella F, Link W, Carnero A
Understanding FOXO, new views on old transcription factors.
Curr Cancer Drug Targets 2010 Mar;10(2):135-46.
Kühnel F, Gürlevik E, Wirth TC, Strüver N, Malek NP, Müller-Schilling M, Manns MP, Carnero A, Zender L, Kubicka S.
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.
Mol Ther. 2010 May;18(5):936-46.
Ramos-Lima FJ, Moneo V, Quiroga AG, Carnero A, Navarro-Ranninger C
The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine.
Eur J Med Chem. 2010 Jan;45(1):134-41.
Carnero A.
The PKB/AKT pathway in cancer.
Current Pharmacological Design 2010 :16 (1):34-44.
Santibanez JF, Pérez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, Malumbres M, Vary CP, Quintanilla M, Bernabéu C.
The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras.
Carcinogenesis. 2010 Dec;31(12):2145-54.
Vergel M, Carnero A.
Bypassing cellular senescence by genetic screening tools.
Clin Transl Oncol. 2010 Jun;12(6):410-7.
Zanella F, Renner O, García B, Callejas S, Dopazo A, Carnero A, Link,W.
Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.
Oncogene 2010: 29(20):2973-82.
Zanella F, Carnero A
Adding more content to screening: reactivation of FOXO as a therapeutic strategy.
Clin Transl Oncol. 2009 Oct;11(10):651-8.
Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A
Inhibiting PI3K as a therapeutic strategy against cancer.
Clin Transl Oncol. 2009 Sep;11(9):572-9.
Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebriá A, Alfonso P, Fominaya J, Renner O, Peregrina S, Soilán D, Ceballos PA, Hernández AI, Lorenzo M, Pevarello P, Granda TG, Kurz G, Carnero A, Bischoff JR
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
J Biol Chem. 2009 Oct 9;284(41):28392-400.
Carnero A
Novel inhibitors of the PI3K family.
Expert opinion on investigational drugs 2009 Sep;18(9):1265-77
Urosevic J, Sum EY, Moneo V, Drosten M, Dhawahir A, Becerra M, Carnero A, Barbacid M
Using cells devoid of RAS proteins as tools for drug discovery.
Molecular carcinogenesis 2009 Nov;48(11):1038-47
Zanella F, Rosado A, Garcia B, Carnero A, Link W
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators.
BMC cell biology 2009 ;10():14
Artero-Castro A, Callejas FB, Castellvi J, Kondoh H, Carnero A, Fernández-Marcos PJ, Serrano M, Ramón y Cajal S, Lleonart ME
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation.
Molecular and cellular biology 2009 Apr;29(7):1855-68
Renner O, Carnero A
Mouse models to decipher the PI3K signaling network in human cancer.
Current molecular medicine 2009 Jun;9(5):612-25
Cubo L, Quiroga AG, Zhang J, Thomas DS, Carnero A, Navarro-Ranninger C, Berners-Price SJ.
Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.
Dalton Trans. 2009 May 14;(18):3457-66.
Renner O, Blanco-Aparicio C, Grassow M, Cañamero M, Leal JF, Carnero A
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Cancer research 2008 Dec;68(23):9643-53
Ruiz L, Traskine M, Ferrer I, Castro E, Leal JF, Kaufman M, Carnero A
Characterization of the p53 response to oncogene-induced senescence.
PloS one 2008 ;3(9):e3230
Leal JF, Ferrer I, Blanco-Aparicio C, Hernández-Losa J, Ramón Y Cajal S, Carnero A, Lleonart ME
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis.
Carcinogenesis 2008 Nov;29(11):2089-95
Zanella F, Carnero A
Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.
EMBO reports 2008 Sep;9(9):853-8
Castro ME, Leal JF, Lleonart ME, Ramon Y Cajal S, Carnero A
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function.
Carcinogenesis 2008 Jul;29(7):1343-50
Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Current cancer drug targets 2008 May;8(3):187-98
Leal JF, Fominaya J, Cascón A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon Y Cajal S, Robledo M, Beach DH, Carnero A
Cellular senescence bypass screen identifies new putative tumor suppressor genes.
Oncogene 2008 Mar;27(14):1961-70
Medina RM, Rodríguez J, Quiroga AG, Ramos-Lima FJ, Moneo V, Carnero A, Navarro-Ranninger C, Macazaga MJ.
Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes.
Chem Biodivers. 2008 Oct;5(10):2090-100.
Guijarro MV, Link W, Rosado A, Leal JF, Carnero A
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.
Carcinogenesis 2007 Dec;28(12):2443-50
Rodríguez-Antona C, Leskelä S, Zajac M, Cuadros M, Alvés J, Moneo MV, Martín C, Cigudosa JC, Carnero A, Robledo M, Benitez J, Martínez-Delgado B
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Blood 2007 Nov;110(9):3345-51
Quereda V, Martinalbo J, Dubus P, Carnero A, Malumbres M
Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression.
Oncogene 2007 Dec;26(55):7665-74
Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sánchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A.
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
J Cell Biochem. 2007 Feb 1;100(2):339-48.
Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramon y Cajal S, Carnero A.
MAP17 enhances the malignant behavior of tumor cells through ROS increase.
Carcinogenesis. 2007 Oct;28(10):2096-104.
Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A.
Levels of p27(kip1) determine Aplidin sensitivity.
Mol Cancer Ther. 2007 Apr;6(4):1310-6.
Cepero V, García-Serrelde B, Moneo V, Blanco F, González-Vadillo AM, Alvarez-Valdés A, Navarro-Ranninger C, Carnero A.
Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.
Clin Transl Oncol. 2007 Aug;9(8):521-30.
Ramos-Lima FJ, Quiroga AG, García-Serrelde B, Blanco F, Carnero A, Navarro-Ranninger C.
New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.
J Med Chem. 2007 May 3;50(9):2194-9. Epub 2007 Apr 4.
González-Vadillo AM, Alvarez-Valdés A, Moneo V, Blanco F, Díaz RG, Carnero A, Navarro-Ranninger C.
Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death.
J Inorg Biochem. 2007 Apr;101(4):551-8. Epub 2006 Nov 30.
Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon Y Cajal S, Carnero A.
MAP17 overexpression is a common characteristic of carcinomas.
Carcinogenesis. 2007 Aug;28(8):1646-52.
Renner O, Fominaya J, Alonso S, Blanco-Aparicio C, Leal JF, Carnero A.
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
Carcinogenesis. 2007 Jul;28(7):1418-25.
Blanco-Aparicio C, Pérez-Gallego L, Pequeño B, Leal JF, Renner O, Carnero A.
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.
Carcinogenesis. 2007 Mar;28(3):584-94.
Carnero A.
The PI3K pathway in cancer.
In: “Systems Biology of Cancer”., Dr. Sam THIAGALINGAM © 2010 (ed.)
Paz-Ares L, Carnero A.
Between bench and bed side: PI3K inhibitors.
Curr Mol Pharmacol. 2010 Jun;3(2):79-90.
Vergel M, Marin JJ, Estevez P, Carnero A.
Cellular senescence as a target in cancer control.
J Aging Res. 2010 Dec 30;2011:725365.
